Wismilak Inti Makmur Tbk (WIIM)
Jakarta Exchange · Indonesia · prices in IDR · close of 22 Oct 2026
Key indicators
| Last close | IDR 1,430.00 |
|---|---|
| 52-week range | 1,115.00 – 2,160.00 |
| Return, 1 month / 3 months | −2.7% / −11.7% |
| Return, 1 year / 3 years | +34.5% / −44.4% |
| Trend | Below its 200-day average |
| RSI (14) | 46 |
| Volatility (1 year) | 57.7% |
| Worst drawdown (1 year) | -37.2% |
| Average daily value traded | 3,470.10M IDR |
| Dividend yield | 7.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Wismilak Inti Makmur Tbk is an Indonesian tobacco company that makes cigarettes, including clove-based kretek cigarettes and milder cigarette varieties. It produces and markets its own cigarette brands and also supplies tobacco products to adult smokers in Indonesia and to export markets. The company is based in Indonesia and handles manufacturing, branding and distribution of its cigarette lines, with a product range that spans traditional kretek and other cigarette styles for domestic and international customers.
The shares are listed on the Jakarta Exchange in Indonesia under the code WIIM, and the price on this page is in Indonesian rupiah (IDR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Wismilak Inti Makmur Tbk (WIIM) trades on the Jakarta Exchange in Indonesia. It last closed at IDR 1,430.00 on 22 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 290 of 923 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 34.5% and over the last three months it fell 11.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Jakarta Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -14.3% | ||
| From 52-week high | -31.9% | ||
| Momentum | 59 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -11.7% | ||
| 6-month return | -13.4% | ||
| 12-month return, skipping the last month | 38.3% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 57.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.2% | ||
| Liquidity | 70 · Fair | Moderate trading activity. | |
| Average daily value traded | 3,470.10M IDR | ||
| Zero-volume days | 3.3% | ||
| Income | 73 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 7.3% | ||
| Years with dividends | 5 |
Strengths
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −2.7% |
|---|---|
| 1 month | −2.7% |
| 3 months | −11.7% |
| 6 months | −13.4% |
| 1 year | +34.5% |
| 3 years | −44.4% |
| 5 years | +285.6% |
Signals
| 50-day / 200-day average | 1,560.80 / 1,667.88 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 77.11 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 May 2026 | IDR 104.4000 |
| 10 Jun 2025 | IDR 64.8000 |
| 5 Jun 2024 | IDR 107.1000 |
| 9 Jun 2023 | IDR 72.9000 |
| 6 Jul 2022 | IDR 21.6000 |
| 5 Aug 2021 | IDR 20.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Jakarta Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.